$5.75
+0.12 (+2.13%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where PRLD is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
12 interventional
Held by 7 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, MARSHALL WACE, LLP, Squarepoint Ops LLC, +2 more) · FINRA short interest 9.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsNCT07469891Dose limiting toxicity (DLT) of PRT12396Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: PRT12396 | Polycythemia Vera (PV), Myelofibrosis (MF), Myeloproliferative Neoplasms (MPNs), Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, Primary Myelofibrosis (PMF) | 100 | Apr 2028 | ≤ 620 d | 2026-07-31 |
| A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 MutationNCT06560645Dose Limiting toxicity (DLT) of PRT7732Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision | Drug: PRT7732 | Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Carcinoma, SMARCA4 Mutation, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Squamous Cell Carcinoma | 42 | 2026-01-28actual | — | 2026-02-02 |
| A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 MutationNCT06682806Safety and tolerability of PRT3789 in combination with pembrolizumab as measured by incidence of DLTs (Part 1)Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: PRT3789, pembrolizumab | Advanced Solid Tumor, Esophageal Cancer, Metastatic Solid Tumor, Non-small Cell Lung Cancers, SMARCA4 Gene Mutation | 6 | 2026-01-23actual | — | 2026-02-02 |
| PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 MutationNCT05639751Dose limiting toxicity (DLT) of PRT3789 monotherapy and in combination with docetaxelNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: PRT3789, Docetaxel | Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancers, SMARCA4 Gene Mutation | 135 | 2025-10-01actual | — | 2025-10-16 |
| A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic MalignanciesNCT05665530Dose limiting toxicity (DLT) of PRT2527Non-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: PRT2527, Zanubrutinib, Venetoclax | Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL), Richter's Syndrome, T-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma, Myeloid Malignancies, Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS), MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome | 86 | 2025-06-12actual | — | 2026-01-26 |
| A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid TumorsNCT05538572Dose limiting toxicity (DLT) of PRT3645Open-label · Treatment | Phase 1 | Completed | Drug: PRT3645 | Breast Cancer, Glioblastoma, Head and Neck Squamous Cell Carcinoma, Malignant Mesothelioma, Non-small Cell Lung Cancers, Sarcoma, Endometrial Cancer | 22 | 2024-06-26actual | — | 2024-07-01 |
| PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell MalignanciesNCT05107856Dose limiting toxicities (DLT) of PRT1419Non-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Company Decision | Drug: PRT1419, Azacitidine, Venetoclax | Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelomonocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Small Lymphocytic Lymphoma | 21 | 2024-01-19actual | — | 2024-01-31 |
| A Study of PRT2527 in Participants With Advanced Solid TumorsNCT05159518Dose limiting toxicities (DLT) of PRT2527Open-label · Treatment | Phase 1 | Completed | Drug: PRT2527 | Sarcoma, Castrate Resistant Prostate Cancer, Hormone Receptor Positive HER2 Negative Breast Cancer, Non-small Cell Lung Cancer, Solid Tumors With Known MYC Amplification | 30 | 2023-12-06actual | — | 2023-12-11 |
| A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and GliomasNCT04089449To describe dose limiting toxicities (DLT) of PRT811Open-label · Treatment | Phase 1 | Completed | Drug: PRT811 | Advanced Solid Tumor, Recurrent Glioma | 86 | 2023-03-28actual | — | 2023-04-05 |
| A Study of PRT1419 in Patients With Advanced Solid TumorsNCT04837677Dose limiting toxicities (DLT) of PRT1419Open-label · Treatment | Phase 1 | Completed | Drug: PRT1419 | Sarcoma, Melanoma, Lung Cancer, Breast Cancer, Esophageal Cancer, Cervical Cancer, Head and Neck Cancer | 26 | 2023-02-06actual | — | 2023-03-15 |
| A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic MalignanciesNCT03886831To describe dose limiting toxicities (DLT) of PRT543Open-label · Treatment | Phase 1 | Completed | Drug: PRT543 | Relapsed/Refractory Advanced Solid Tumors, Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Myelodysplasia, Relapsed/Refractory Myelofibrosis, Adenoid Cystic Carcinoma, Relapsed/Refractory Mantle Cell Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia | 232 | 2022-11-16actual | — | 2023-03-28 |
| A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic MalignanciesNCT04543305To describe dose limiting toxicities (DLT) of PRT1419Open-label · Treatment | Phase 1 | Completed | Drug: PRT1419 | Multiple Myeloma, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Myelodysplastic Syndromes | 16 | 2022-03-21actual | — | 2022-11-15 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19